ValuEngine Upgrades Hologic (NASDAQ:HOLX) to “Hold”
A number of other equities research analysts also recently issued reports on the stock. Bank of America raised shares of Hologic from a neutral rating to a buy rating and upped their price target for the company from $54.00 to $59.00 in a research note on Thursday, September 26th. BTIG Research reaffirmed a buy rating and set a $52.00 price target on shares of Hologic in a research note on Thursday, August 1st. Canaccord Genuity reduced their target price on shares of Hologic from $52.00 to $50.00 and set a hold rating on the stock in a research note on Monday, November 11th. BidaskClub downgraded shares of Hologic from a hold rating to a sell rating in a research note on Thursday, November 7th. Finally, Zacks Investment Research raised shares of Hologic from a hold rating to a buy rating and set a $54.00 target price on the stock in a research note on Friday, August 16th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company. Hologic currently has a consensus rating of Hold and an average price target of $51.19.
Hologic stock traded up $0.31 during mid-day trading on Wednesday, reaching $49.50. 3,500,200 shares of the company’s stock traded hands, compared to its average volume of 1,875,415. The company has a market cap of $12.60 billion, a price-to-earnings ratio of 20.37, a PEG ratio of 2.06 and a beta of 0.76. The stock has a 50 day moving average of $48.24 and a two-hundred day moving average of $48.11. The company has a quick ratio of 1.26, a current ratio of 1.68 and a debt-to-equity ratio of 1.22. Hologic has a 12-month low of $37.48 and a 12-month high of $52.19.
In other Hologic news, insider Peter J. Valenti III sold 7,766 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $49.14, for a total transaction of $381,621.24. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Stephen P. Macmillan sold 194,396 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $45.91, for a total transaction of $8,924,720.36. The disclosure for this sale can be found here. Corporate insiders own 0.90% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Grantham Mayo Van Otterloo & Co. LLC bought a new position in Hologic during the 2nd quarter worth about $325,000. McGuire Investment Group LLC grew its holdings in Hologic by 20.6% during the 2nd quarter. McGuire Investment Group LLC now owns 96,190 shares of the medical equipment provider’s stock worth $4,619,000 after acquiring an additional 16,446 shares in the last quarter. Fox Run Management L.L.C. bought a new position in Hologic during the 2nd quarter worth about $576,000. Paloma Partners Management Co bought a new position in Hologic during the 2nd quarter worth about $4,243,000. Finally, Natixis bought a new position in Hologic during the 2nd quarter worth about $4,191,000. Institutional investors own 96.98% of the company’s stock.
Hologic Company Profile
Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.